Leap Therapeutics, Inc. (LPTX): Price and Financial Metrics
LPTX Stock Summary
- For LPTX, its debt to operating expenses ratio is greater than that reported by merely 4.7% of US equities we're observing.
- LPTX's price/sales ratio is 108.18; that's higher than the P/S ratio of 96.75% of US stocks.
- As for revenue growth, note that LPTX's revenue has grown 200% over the past 12 months; that beats the revenue growth of 96.81% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Leap Therapeutics Inc, a group of peers worth examining would be GSIT, EDIT, XFOR, ARCT, and FPRX.
- LPTX's SEC filings can be seen here. And to visit Leap Therapeutics Inc's official web site, go to www.leaptx.com.
LPTX Stock Price Chart Interactive Chart >
LPTX Price/Volume Stats
|Current price||$2.08||52-week high||$3.24|
|Prev. close||$2.04||52-week low||$1.15|
|Day high||$2.17||Avg. volume||858,755|
|50-day MA||$2.42||Dividend yield||N/A|
|200-day MA||$2.09||Market Cap||124.09M|
Leap Therapeutics, Inc. (LPTX) Company Bio
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in acquiring and developing therapeutics in cancer biology. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
LPTX Latest News Stream
|Loading, please wait...|
LPTX Latest Social Stream
View Full LPTX Social Stream
Latest LPTX News From Around the Web
Below are the latest news stories about Leap Therapeutics Inc that investors may wish to consider to help them evaluate LPTX as an investment opportunity.
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the following virtual investor conferences:
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASD...
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at…
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference. The conference will be held in a virtual meeting format.
In this article you are going to find out whether hedge funds think LEAP THERAPEUTICS, INC. (NASDAQ:LPTX) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
LPTX Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!